2026 Q1 -tulosraportti
UUTTA
3 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,03%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 570 | - | - | ||
| 1 430 | - | - | ||
| 5 000 | - | - | ||
| 3 570 | - | - | ||
| 1 430 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8 t sittenAs I interpret Q1, Eli has not cut prices as much as Novo, but rather awaits the development and results of the drastic measures Novo has taken. Thus, a more reactive stance. This could lead to Eli being pressured to a greater extent into 2026 with declining revenues and that Novo's market position will strengthen. Thoughts on this
·3 t sittenI think that MAGA favors Eli... among other things with tax cuts. Of course, the idea is completely insane, but with that administration's morals and ethics, combined with, among other things, hedge funds' gigantic financial muscle, it seems very plausible to me. NOVO down Eli Lilly up
·2 t sittenNo doubt that MAGA favors American companies and jobs and that a lot of obstacles are put in the way for Novo. But let's see. I am more bullish on Novo now.
·10 t sittenI think it's wild, when we see all the side effects on GLP1 that are emerging. Which can be worth several hundred billions, that the price has fallen 30-40 percent because NN has disappointed by 1-2 percent on weight loss.
·3 t sitten · MuokattuX10X, you keep hyping up news to something completely wild for Novo Nordisk. Now stick to the facts. The share price of Novo Nordisk is pressured down because earnings will fall significantly in the future. Already at the beginning of next year, the price agreements they have entered into in the USA will come into effect. Then their margins will fall, again, sharply. According to all expectations, this will also start price pressure in their other important markets - and suddenly we are approaching the expiration of the patents on semaglutide. Now we are also starting to see other companies on their way with GLP-1 agents, some have advantages such as they only need to be taken once a month etc. If Novo Nordisk is outcompeted on GLP-1/2, what is really left? You skillfully avoid addressing the above. I can well understand that by now some people are thoroughly annoyed with you. All your considerations are, in my assessment, far too rosy, and you generally refuse to address the financial statements - now and in the future. For you, it is always the 10 birds on the roof that are highlighted.
·6 min sittenX10X, you're doing fine, and are absolutely not off the mark. I appreciate your posts. Please continue. Thanks
·22 t sittenNOVO makes a deal with NICE UK Let's get more of those kinds of deals that have some meat on them. https://x.com/drbennisahmed/status/2052803719725490454·12 t sittenChat GPT answer to the agreement 😊 But the really big value might not lie in the UK alone. The market thinks more like this: "If NICE accepts GLP-1 for the prevention of blood clots and stroke — will the rest of Europe follow suit?" Because if: * Germany * France * Canada * Japan * parts of Medicare/USA start to reimburse in the same way, then we are suddenly talking about a global market of many hundreds of billions of kroner over time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
UUTTA
3 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,03%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenAs I interpret Q1, Eli has not cut prices as much as Novo, but rather awaits the development and results of the drastic measures Novo has taken. Thus, a more reactive stance. This could lead to Eli being pressured to a greater extent into 2026 with declining revenues and that Novo's market position will strengthen. Thoughts on this·3 t sittenI think that MAGA favors Eli... among other things with tax cuts. Of course, the idea is completely insane, but with that administration's morals and ethics, combined with, among other things, hedge funds' gigantic financial muscle, it seems very plausible to me. NOVO down Eli Lilly up·2 t sittenNo doubt that MAGA favors American companies and jobs and that a lot of obstacles are put in the way for Novo. But let's see. I am more bullish on Novo now.
- ·10 t sittenI think it's wild, when we see all the side effects on GLP1 that are emerging. Which can be worth several hundred billions, that the price has fallen 30-40 percent because NN has disappointed by 1-2 percent on weight loss.·3 t sitten · MuokattuX10X, you keep hyping up news to something completely wild for Novo Nordisk. Now stick to the facts. The share price of Novo Nordisk is pressured down because earnings will fall significantly in the future. Already at the beginning of next year, the price agreements they have entered into in the USA will come into effect. Then their margins will fall, again, sharply. According to all expectations, this will also start price pressure in their other important markets - and suddenly we are approaching the expiration of the patents on semaglutide. Now we are also starting to see other companies on their way with GLP-1 agents, some have advantages such as they only need to be taken once a month etc. If Novo Nordisk is outcompeted on GLP-1/2, what is really left? You skillfully avoid addressing the above. I can well understand that by now some people are thoroughly annoyed with you. All your considerations are, in my assessment, far too rosy, and you generally refuse to address the financial statements - now and in the future. For you, it is always the 10 birds on the roof that are highlighted.·6 min sittenX10X, you're doing fine, and are absolutely not off the mark. I appreciate your posts. Please continue. Thanks
- ·22 t sittenNOVO makes a deal with NICE UK Let's get more of those kinds of deals that have some meat on them. https://x.com/drbennisahmed/status/2052803719725490454·12 t sittenChat GPT answer to the agreement 😊 But the really big value might not lie in the UK alone. The market thinks more like this: "If NICE accepts GLP-1 for the prevention of blood clots and stroke — will the rest of Europe follow suit?" Because if: * Germany * France * Canada * Japan * parts of Medicare/USA start to reimburse in the same way, then we are suddenly talking about a global market of many hundreds of billions of kroner over time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 570 | - | - | ||
| 1 430 | - | - | ||
| 5 000 | - | - | ||
| 3 570 | - | - | ||
| 1 430 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
UUTTA
3 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
4,03%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenAs I interpret Q1, Eli has not cut prices as much as Novo, but rather awaits the development and results of the drastic measures Novo has taken. Thus, a more reactive stance. This could lead to Eli being pressured to a greater extent into 2026 with declining revenues and that Novo's market position will strengthen. Thoughts on this·3 t sittenI think that MAGA favors Eli... among other things with tax cuts. Of course, the idea is completely insane, but with that administration's morals and ethics, combined with, among other things, hedge funds' gigantic financial muscle, it seems very plausible to me. NOVO down Eli Lilly up·2 t sittenNo doubt that MAGA favors American companies and jobs and that a lot of obstacles are put in the way for Novo. But let's see. I am more bullish on Novo now.
- ·10 t sittenI think it's wild, when we see all the side effects on GLP1 that are emerging. Which can be worth several hundred billions, that the price has fallen 30-40 percent because NN has disappointed by 1-2 percent on weight loss.·3 t sitten · MuokattuX10X, you keep hyping up news to something completely wild for Novo Nordisk. Now stick to the facts. The share price of Novo Nordisk is pressured down because earnings will fall significantly in the future. Already at the beginning of next year, the price agreements they have entered into in the USA will come into effect. Then their margins will fall, again, sharply. According to all expectations, this will also start price pressure in their other important markets - and suddenly we are approaching the expiration of the patents on semaglutide. Now we are also starting to see other companies on their way with GLP-1 agents, some have advantages such as they only need to be taken once a month etc. If Novo Nordisk is outcompeted on GLP-1/2, what is really left? You skillfully avoid addressing the above. I can well understand that by now some people are thoroughly annoyed with you. All your considerations are, in my assessment, far too rosy, and you generally refuse to address the financial statements - now and in the future. For you, it is always the 10 birds on the roof that are highlighted.·6 min sittenX10X, you're doing fine, and are absolutely not off the mark. I appreciate your posts. Please continue. Thanks
- ·22 t sittenNOVO makes a deal with NICE UK Let's get more of those kinds of deals that have some meat on them. https://x.com/drbennisahmed/status/2052803719725490454·12 t sittenChat GPT answer to the agreement 😊 But the really big value might not lie in the UK alone. The market thinks more like this: "If NICE accepts GLP-1 for the prevention of blood clots and stroke — will the rest of Europe follow suit?" Because if: * Germany * France * Canada * Japan * parts of Medicare/USA start to reimburse in the same way, then we are suddenly talking about a global market of many hundreds of billions of kroner over time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 570 | - | - | ||
| 1 430 | - | - | ||
| 5 000 | - | - | ||
| 3 570 | - | - | ||
| 1 430 | - | - |
Välittäjätilasto
Dataa ei löytynyt